Welcome to our dedicated page for Agenus SEC filings (Ticker: AGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing Agenus Inc.鈥檚 immuno-oncology disclosures can feel like decoding lab notebooks鈥攈undreds of pages packed with trial endpoints, milestone payments, and manufacturing risks. If you鈥檝e ever wondered how to locate breakthrough data or track executive stock sales before a catalyst, you鈥檙e not alone.
Stock Titan delivers AI-powered summaries that turn every Agenus SEC document into plain English. Whether you need the Agenus quarterly earnings report 10-Q filing for burn-rate analysis, an Agenus 8-K material events explained alert on new clinical results, or Agenus insider trading Form 4 transactions to monitor buying and selling, our platform updates in real time as soon as EDGAR posts.
Here鈥檚 how investors use it:
- Receive push notifications for Agenus Form 4 insider transactions real-time and spot buying patterns.
- Dive into an Agenus annual report 10-K simplified view that highlights cash runway, collaboration revenue, and cGMP manufacturing commitments.
- Compare pipeline progress across quarters with succinct Agenus earnings report filing analysis.
- Access the latest Agenus proxy statement executive compensation details without sifting through appendices.
Every filing鈥�10-K, 10-Q, 8-K, S-1, and more鈥攊s indexed, searchable, and paired with concise expert context, ensuring understanding Agenus SEC documents with AI is straightforward. No more scrolling through dense scientific jargon; the critical insights are surfaced for you.
Agenus Inc. reported a six-month net loss of $56.4 million and a weighted average basic and diluted loss per share of $2.03. Cash and cash equivalents were $9.5 million at June 30, 2025, and the company had an accumulated deficit of $2.2 billion and total assets of $185.2 million. The balance sheet shows a large recorded liability related to sale of future royalties and milestones, net of $312.2 million, current liabilities of $234.6 million and stockholders鈥� deficit attributable to Agenus of $354.6 million.
The company received $75.0 million gross proceeds from the Ligand Purchase Agreement (allocated partly to a royalty liability) and recognized $48.4 million of non-cash royalty revenue in the six months. Subsequent to quarter end it sold ~787,000 shares for net proceeds of ~$5.2 million and expects to receive $75.0 million upfront plus a $16.0 million equity investment from the Zydus transaction upon closing in Q3 2025. Management discloses substantial doubt about going concern for one year after filing and notes ongoing litigation and an SEC subpoena.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,407 shares of common stock in lieu of cash salary for the pay period ending August 8, 2025. The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and the company reports a closing price of $4.80 on August 8, 2025.
After the issuance, Dr. Armen directly beneficially owns 267,311 shares. He also reports 31,298 shares held in his IRA accounts and 28,950 shares held indirectly through a GRAT and a partnership where he has a partial pecuniary interest. The filing states the issued shares are fully vested on the date of issuance.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
